**Lily Gorman**

**Willington, CT 06279 - lily.gorman@uconn.edu**

**EDUCATION**

**PhD Student in Human Development and Family Sciences** Estimated May 2029

University of Connecticut, Storrs, CT

Planned Graduate Certificates in Health Psychology and College Instruction

**Bachelor of Arts in Psychology, Minors in Neuroscience and Spanish** May 2020

Salve Regina University, Newport, RI GPA: 3.9, Summa Cum Laude, Dean’s List, Pell Honors Program

Semester Abroad,CEA Liberal Arts and Social Sciences Program: Barcelona, Spain Fall 2018

**WORK EXPERIENCE**

**Teaching Assistant,** University of Connecticut, Storrs, CT August 2024-Present

* Grade written assignments and assess assignment participation
* Communicate with 300+ undergraduate students via email and face-to-face interaction
* Manage and coordinate accommodations for student disabilities
* Attend class lectures and assist students with in-class assignments
* Lead student discussion sections on sensitive and meaningful topics
* Classes: HDFS-1070 Individual and Family Development, HDFS-2001 Diversity Issues in HDFS

**Senior Research Supervisor,** Boston Center for Memory, Newton, MA August 2022-August 2024

* Design and implement new study tools, spreadsheets, and source documents to improve clinic efficiency
* Provide training and oversight to research assistant(s) regarding clinical trial administrative assistance
* Act as a back-up for laboratory staff and clinical research coordinators for other trials when necessary
* Assist coordinators with study start-up activities and regulatory documentation and maintenance
* Develop, maintain, and ensure adherence to the site’s clinical research Standard Operating Procedures
* Continue Clinical Research Coordinator I role via several multisite Alzheimer’s Disease clinical research trials

**Clinical Research Coordinator I,** Boston Center for Memory, Newton, MA October 2021-August 2022

* Coordinate patient visits and protocol-directed procedures for multiple Alzheimer’s Disease clinical research trials
* Adhere to institutional standard operating procedures, as well as all IRB and protocol-specific requirements
* Maintain study databases, regulatory information, and correspondence with patients, study sponsors, and vendors
* Recruit and screen potential subjects from the clinic’s patient database to enrolling study protocols
* Communicate with, and relay information between patients/caregivers, medical staff, study sponsors, PI/Sub-I’s, etc.
* Conduct neuropsychological assessments to clinic trial subjects per protocol guidelines and GCP standards

**Research and Laboratory Assistant,** Boston Center for Memory, Newton, MA June 2021-October 2021

* Perform laboratory duties for Alzheimer’s Disease clinical trials, such as blood sample processing and preparation
* Oversee IP administration and patient care under supervision of pharmacists, physicians, and laboratory coordinator
* Assist coordinators with data entry, document filing, source creation, scheduling, and database maintenance
* Collect vitals and perform EKGs, as necessary
* Ensure biological samples are shipped in compliance with all local, state, and federal regulations
* Maintain patient safety by responding to infusion-reactions and other medical emergencies when required

**WORK EXPERIENCE CONTINUED**

**Registered Behavior Technician,** Confidence Connection, Needham, MA August 2020-April 2021

* Provide 1:1 ABA therapy to children with autism spectrum disorders to improve their communication, language, and play skills, and collect data to track each individual’s progress
* Run social groups to facilitate play and communication between peers

**Home-Based Behavioral Technician**, J. Arthur Trudeau Memorial Center, Warwick, RI October 2019-July 2020

* Work one on one with clients with behavioral and intellectual disabilities in order to perform behavioral intervention programs established by a board-certified behavior analyst

**Special Education Assistant**, Dennis-Yarmouth Regional School District, MA July 2019-August 2019

* Assisted teachers in facilitating summer program activities for students with neurodevelopmental disabilities

**CLINICAL TRIAL EXPERIENCE,** *Multi-Center Trials*

**Sub-Investigator,** Boston Center for Memory

* Acumen Pharmaceuticals Inc.
  + ACU193-201: A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer’s Disease
* AriBio USA, Inc.
  + AR1001-ADP3-US01: A Phase 3 Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease
* Athira Pharma, Inc.
  + ATH-1017-AD-0201: A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer’s Disease
* Biogen MA Inc.
  + 221AD304: Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects with Alzheimer’s Disease who had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302, and 221AD205
  + 221AD305: A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease
  + 247AD201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
* Bristol-Myers Squibb Company
  + CN008-0003: A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
* Cassava Sciences, Inc.
  + PTI-125-06: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects with Mild-to-Moderate Alzheimer’s Disease
  + PTI-125-10: An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100mg Tablets in Participants with Mild to Moderate Alzheimer’s Disease

**CLINICAL TRIAL EXPERIENCE CONTINUED,** *Multi-Center Trials*

**Sub-Investigator,** Boston Center for Memory

* Cognito Therapeutics, Inc.
  + CA-0011: A Randomized, Double-blind, Sham-controlled, Adaptive- Design Pivotal Study of Sensory Stimulation in Subjects with Alzheimer’s Disease
  + CA-0015: Open-Label Extension to a Randomized, Double-blind, Sham-controlled, Adaptive-Design Pivotal Study of Sensory Stimulation in Subjects with Alzheimer’s Disease
* Eisai Inc.
  + BAN2401-G000-301: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease
* Eli Lilly and Company
  + I5T-MC-AACH: Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer’s Disease with Validation of Remote Neuropsychological Assessments
  + I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
  + I5T-MC-AACM: A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
  + I9X-MC-MTAE: Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease
  + J4Y-MC-B002: Evaluation of the Lilly SP-X P-tau217 Assay by Measuring Changes in the Intended Patient Management between Pre- and Post-P-tau217 Result: A Randomized Clinical Utility Study
* Merck Sharp & Dohme LLC
  + MK-1167-008-00: A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group, Study to Evaluate the Efficacy and Safety or MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia
* UCB Biopharma SRL
  + AH0003: A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants with Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period

**Laboratory Assistant,** Boston Center for Memory

* Biogen MA Inc.
  + 251AD201: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease or with Mild Alzheimer’s Disease
* Cognito Therapeutics, Inc.
  + CA-0004:Multi-Center Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function
  + CA-0005: Multi-Center Study of Sensory Stimulation to Improve Brain Function
* Cortexyme, Inc.
  + COR388-010:A Randomized, Double-Blind, Placebo-Controlled Study of COR388 HCl in Subjects with Alzheimer’s Disease
* Eli Lilly and Company
  + Protocol I8G-MC-LMDC: Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer’s Disease

**CLINICAL TRIAL EXPERIENCE CONTINUED,** *Multi-Center Trials*

**Laboratory Assistant,** Boston Center for Memory

* F. Hoffman-La Roche Ltd
  + WN39658: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer’s Disease
  + WN42171: An Open-Label, Multicenter, Rollover Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants with Alzheimer's Disease

**SKILLS**

**Computer Skills:** SPSS Statistics Software, Qualtrics, Microsoft Office Suite, Google G-Suite, Zoom, Skype, FileMaker, InForm, Veeva, iMedidata, Pentara, MedAvante-ProPhase, Zelta, Clario, Calyx, Suvoda, Cenduit, Medrio, Signant Health

**Languages:** English (fluent), Spanish (moderate)

**Certifications:** Good Clinical Practice, Transporting Dangerous Goods (IATA), Fundamentals of Digital Research,

American Red Cross CPR/AED, Child CPR, & First Aid, Safety-Care, Registered Behavior Technician,

**Cognitive Assessment Administration Qualification:** CSSRS, MOCA

**Training in progress:** MMSE, TICS, EQ-5D, and mPDQ-20

**RESEARCH EXPERIENCE**

**Developmental Psychology,** Naughty or Nice? The Effects of a Santa Claus Belief on Emotional Intelligence: 2020

* Presented at the annual American Psychological Association Conference, 2021

**Neuroscience,** The Neurodevelopmental Effects of Developmental PFOS Exposure in *C. elegans:* 2020

* Under the supervision of Dr. Belinda Barbagallo, Salve Regina University

**Historical Psychology,** The Temporary Insanity Plea: Its First Successful Use, the Public Opinion, and the Murderess

Who Went Free: 2019

* Presented at the New England Psychological Association’s annual meeting in Manchester, NH: 2019

**Cognitive Psychology,** The Effects of Tattoo Size and Gender on Hireability: 2018

* Presented at the annual SRYou Day Conference in Newport, RI: 2018

**Literature Reviews**

* Death and Bereavement within the Family: 2020
* The Benefits of Sign Language for Individuals on the Autism Spectrum: 2019
* A Neurological View of Social Attention and its Diagnostic Ability for Autism: 2018
* The Long-term Psychological Effects of Childhood Trauma: 2018

**LEADERSHIP EXPERIENCE**

**Varsity Captain,** Women’s Tennis Team, Salve Regina University August 2019-May 2020

**Public Relations Coordinator**, Student Networking Association, Salve Regina University Jan 2019-May 2020

**ESL Teaching Assistant,** Escola Mestre Enric Gibert i Camins, Barcelona, Spain Sept 2018-Dec 2018

**CONTINUING EDUCATION UNITS**

* Spotting the Signs of Mild Cognitive Impairment, APA July 2024
* Assisted Dying: The Motivations Benefits and Pitfalls of Hastening Death, APA October 2024
* How Psychologists Can Bring Their Expertise to End-of-Life Care, APA October 2024